Targeting bacterial membrane proteins for new antimicrobial strategies

细菌抗生素耐药性是公共卫生和生物防御领域的全球健康挑战，但大型制药公司开发的新抗生素正在减少。学术和生物技术公司正在填补该领域的空白，从而开发出新的治疗技术，可以提供新的安全有效的抗生素。我们将与Dstl合作，利用各种新方法研究选定病原体中负责细胞壁生物合成的膜蛋白复合物。我们将重点关注细菌细胞壁的组装，这是现有抗生素的有效靶点，在过去十年中，从机制研究和细菌细胞生物学的进展中获得的新见解，为这一过程提供了新的机会和理解，为新抗生素的发现提供了新的视角。www.warwick.ac.uk /去/ ropergroup

Bacterial antibiotic resistance is a global health challenge in both public health and biodefence but new antibiotic development by large pharma is in decline. The void in the sector is being filled by academic and biotech companies leading to the development of new therapeutic technologies that can provide new safe and effective antibiotics. We will collaborate with Dstl to investigate the membrane protein complexes responsible for cell wall biosynthesis in selected pathogens using a variety of new approaches. We will focus on the assembly of the bacterial cell wall, a validated target for existing antibiotics where novel insight in the past decade from mechanistic studies and advances in bacterial cell biology, have provided new opportunity and understanding related to this process offering fresh perspectives in new antibiotic discovery. www.warwick.ac.uk/go/ropergroup